XRAY · DENTSPLY SIRONA Inc.

The thesis

Dentsply Sirona's turnaround case is unproven and the shares have only partly recovered: they closed at $9.50 on 22 October 2026, above the $9.40 level the prior note used as the line for tentative repair and above the $8.83 close of 9 October 2026. The third-quarter report, now confirmed for 5 November 2026, settles whether the planned earnings step-up is real.

The narrative is maturing: the story is well known, and the newest news is analyst target cuts, from Leerink Partners on 14 October 2026 and Mizuho on 22 October 2026. The shares fell 27.0% over three months and sit 35.3% below the 52-week high of $14.68, per adjusted daily closes. No result has arrived since the last note, so the rating stays low. The bounce is a price move; the operating test is still ahead.

Bullish and bearish views on DENTSPLY SIRONA Inc.

The bull case on DENTSPLY SIRONA Inc. (XRAY), in brief: Annual guidance still stands. The bear case: The dental core is weakest.

Bull case

• Annual guidance still stands. On 6 August 2026 the company kept fiscal 2026 net sales at $3.5–$3.6 billion and adjusted earnings per share at $1.40–$1.50, excluding tariff-refund benefits. A cut would remove this support.
• The Medline Sinclair relationship in Canada took effect 1 September 2026, per a 28 July 2026 company announcement.
• Wellspect keeps growing. Wellspect Healthcare sales rose 7.1% year over year in the second quarter. On 7 October 2026 the unit said its Surity urinary management portfolio may be covered by traditional Medicare for eligible beneficiaries.
• Expectations have reset lower. Leerink Partners cut its target to $10 on 14 October 2026 and Mizuho cut to $12 on 22 October 2026, both keeping neutral-equivalent ratings. BMO cut to $10 from $13 on 17 September 2026 and Piper Sandler to $12 from $14 on 9 October 2026. A report that merely meets reduced guidance faces a lower hurdle than in July.

Bear case

• The dental core is weakest. Orthodontic and Implant Solutions sales fell 13.2% year over year in the same report, so the largest growth hope sits in the segment shrinking fastest.
• Earnings included a one-off. Second-quarter adjusted earnings per share of $0.52 included $0.17 from a $44 million tariff refund, per the 6 August 2026 release. Management excluded tariff effects from the full-year guide.
• Targets keep falling. Four firms have cut targets since 17 September 2026: BMO, Piper Sandler, Leerink Partners and Mizuho. Each kept a neutral-equivalent rating.
• Leverage leaves less room. Net debt to EBITDA (earnings before interest, tax, depreciation and amortization) was 3.2x at the second quarter, unchanged from the first, while share repurchases resumed after the dividend was eliminated.

Price setup

The adjusted close on 22 October 2026 was $9.50. The 14-day relative strength index (RSI) was 65.2 on 22 October 2026, against 36.4 on 9 October 2026, so the shares have moved from weak to firm in under two weeks. The $8.00 level sits below the October low close.

Crowding evidence is thin. No heavy retail attention or insider selling appears in company news, and the company is repurchasing shares. The one crowding-related item is time: the earnings report is 14 days away, and the price has risen into it while analyst targets have fallen.

Catalysts, next 30 days

No upcoming dated catalysts on file — the dated entries below have passed.

Elapsed catalysts

• 5 November 2026, after the close: Third-quarter 2026 results and conference call at 4:30 p.m. Eastern, per the company's 20 October 2026 announcement. It is the first test of the third-to-fourth-quarter earnings step-up and of the $1.40–$1.50 adjusted earnings guidance. (passed 1d ago)
• Before 5 November 2026, est.: Further analyst target revisions ahead of the report, following the 14 October 2026 and 22 October 2026 cuts. (passed 1d ago)

What would change the view

The repair case breaks if the third-quarter report cuts fiscal 2026 net sales or adjusted earnings guidance, or drops the planned step-up. Another double-digit year-over-year decline in Orthodontic and Implant Solutions sales, after the 13.2% fall reported on 6 August 2026, would also weaken it. A daily close below $8.00 ends it on price.

The case improves if the report confirms the $1.40–$1.50 range without the tariff refund and shows sales declines narrowing in the dental segments. A rating above low needs results that show that, not the price move alone.

What it trades with

Dentsply Sirona trades with dental and medical-device peers and with dental-practice spending, which depends on patient demand for elective procedures. Wellspect, the continence care unit, follows a separate healthcare reimbursement cycle. Net debt of 3.2x EBITDA makes the shares sensitive to interest rates and credit conditions.